PE20020329A1 - DERIVATIVES OF 10-ARYL-11H-BENZO [b] FLUORENE AND ANALOGS AS STROGEN COMPOUNDS - Google Patents

DERIVATIVES OF 10-ARYL-11H-BENZO [b] FLUORENE AND ANALOGS AS STROGEN COMPOUNDS

Info

Publication number
PE20020329A1
PE20020329A1 PE2001000844A PE2001000844A PE20020329A1 PE 20020329 A1 PE20020329 A1 PE 20020329A1 PE 2001000844 A PE2001000844 A PE 2001000844A PE 2001000844 A PE2001000844 A PE 2001000844A PE 20020329 A1 PE20020329 A1 PE 20020329A1
Authority
PE
Peru
Prior art keywords
benzo
fluorene
derivatives
aril
compounds
Prior art date
Application number
PE2001000844A
Other languages
Spanish (es)
Inventor
Zwart Eduard Willem De
Gerrit Herman Veeneman
Jordi Mestres
Hubert Jan Jozef Loozen
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of PE20020329A1 publication Critical patent/PE20020329A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/14—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with at least one hydroxy group on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/17—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings, e.g. cyclohexylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/42—Halogenated derivatives containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings

Abstract

SE REFIERE A DERIVADOS DE 10-ARIL-11H-BENZO[b]FLUORENO DE FORMULA I DONDE Re Y 'Re SON OH OPCIONALMENTE ESTERIFICADO O ETERIFICADO; Z ES CH2, CH2CH2; R1 ES H, HALO, CF3, ALQUILO C1-C4; R2, R3 Y R4 SON H, HALO, CF3, OCF3, ALQUILO C1-C8, HIDROXI, ALQUILOXI C1-C8, ARILOXI, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 10-YODO-2,8-DIHIDROXI-11H-BENZO[b]-FLUORENO, 1O-ARIL-2,8-DIHIDROXI-11H-BENZO[b]FLUORENO, 2,8-DIMETOXI-10-HIDROXI-11H-BENZO[b]FLUORENO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS DERIVADOS DE 10-ARIL-11H-BENZO[b]FLUORENO O 7-ARIL-5,6-DIHIDROBENZ[a]ANTRACENO TIENEN AFINIDAD POR EL RECEPTOR DE ESTROGENOS Y SON UTILES PARA LA PREVENCION O TRATAMIENTO DE HIPERTROFIA PROSTATICA BENIGNA, TRASTORNOS CARDIOVASCULARES, MOLESTIAS MENOPAUSICASREFERS TO 10-ARIL-11H-BENZO [b] FLUORENE DERIVATIVES FROM FORMULA I WHERE Re Y 'Re ARE OH OPTIONALLY STERIFIED OR ETERIFIED; Z IS CH2, CH2CH2; R1 IS H, HALO, CF3, C1-C4 ALKYL; R2, R3 AND R4 ARE H, HALO, CF3, OCF3, C1-C8 ALKYL, HYDROXY, C1-C8 ALKYLOXY, ARYLOXY, AMONG OTHERS. PREFERRED COMPOUNDS ARE 10-IODINE-2,8-DIHYDROXY-11H-BENZO [b] -FLUORENE, 1O-ARIL-2,8-DIHYDROXY-11H-BENZO [b] FLUORENE, 2,8-DIMETOXY-10-HYDROXY- 11H-BENZO [b] FLUORENE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THE DERIVATIVES OF 10-ARIL-11H-BENZO [b] FLUORENE OR 7-ARIL-5,6-DIHIDROBENZ [a] ANTRACENE HAVE AFFINITY FOR THE ESTROGEN RECEPTOR AND ARE USEFUL FOR THE PREVENTION OR TREATMENT OF BENIGN PROSTACTIC HYPERTROPHIA , MENOPAUSAL DISASTERS

PE2001000844A 2000-08-23 2001-08-22 DERIVATIVES OF 10-ARYL-11H-BENZO [b] FLUORENE AND ANALOGS AS STROGEN COMPOUNDS PE20020329A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00202945 2000-08-23

Publications (1)

Publication Number Publication Date
PE20020329A1 true PE20020329A1 (en) 2002-05-08

Family

ID=8171944

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000844A PE20020329A1 (en) 2000-08-23 2001-08-22 DERIVATIVES OF 10-ARYL-11H-BENZO [b] FLUORENE AND ANALOGS AS STROGEN COMPOUNDS

Country Status (24)

Country Link
US (1) US6756375B2 (en)
EP (1) EP1313700B1 (en)
JP (1) JP2004506712A (en)
KR (1) KR20030027052A (en)
CN (1) CN1447791A (en)
AR (1) AR030456A1 (en)
AT (1) ATE309208T1 (en)
AU (1) AU2001282101A1 (en)
BR (1) BR0113444A (en)
CA (1) CA2420289A1 (en)
CZ (1) CZ2003514A3 (en)
DE (1) DE60114850T2 (en)
EC (1) ECSP034488A (en)
ES (1) ES2252273T3 (en)
HU (1) HUP0303718A2 (en)
IL (1) IL154408A0 (en)
IS (1) IS6723A (en)
MX (1) MXPA03001591A (en)
NO (1) NO20030759L (en)
PE (1) PE20020329A1 (en)
PL (1) PL360885A1 (en)
SK (1) SK2052003A3 (en)
WO (1) WO2002016316A1 (en)
ZA (1) ZA200301239B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059920A2 (en) * 1999-04-06 2000-10-12 Akzo Nobel N.V. Orally active 7.alpha.-alkyl androgens
US7157604B2 (en) 2001-08-13 2007-01-02 Merck & Co., Inc. Selective estrogen receptor modulators
TW200304371A (en) * 2002-02-22 2003-10-01 Akzo Nobel Nv Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors
BR0312054A (en) * 2002-06-25 2005-10-18 Wyeth Corp Use of thiooxyindole derivatives in the preparation of medicaments useful in the treatment of hormone related conditions, and pharmaceutical kit
EP1546139A1 (en) 2002-09-25 2005-06-29 Eli Lilly And Company Derivative of dihydro-dibenzo (a) anthracenes and their use as selective estrogen receptor modulators
KR20050071534A (en) * 2002-10-01 2005-07-07 다이닛본 세이야꾸 가부시끼가이샤 Spiro compounds, medicinal compositions containing the same and intermediates of the compounds
WO2004058682A1 (en) * 2002-12-26 2004-07-15 Eisai Co., Ltd. Selective estrogen receptor modulators
US20060173037A1 (en) * 2005-01-10 2006-08-03 Nathalie Schlienger Aminophenyl derivatives as selective androgen receptor modulators
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
EP2647376A1 (en) 2007-01-22 2013-10-09 Gtx, Inc. Nuclear receptor binding agents
WO2015149045A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CN113750091A (en) 2015-04-29 2021-12-07 雷迪厄斯制药公司 Methods for treating cancer
KR20230109795A (en) 2017-01-05 2023-07-20 래디어스 파마슈티컬스, 인코포레이티드 Polymorphic forms of rad1901-2hcl
KR20210030393A (en) 2018-07-04 2021-03-17 래디어스 파마슈티컬스, 인코포레이티드 Polymorphic form of RAD1901-2HCL

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU717251B2 (en) * 1994-12-22 2000-03-23 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US6451817B1 (en) * 1995-03-10 2002-09-17 Eli Lilly And Company Alpha-substituted-1-benzyl-napthyls
CA2214935A1 (en) * 1996-09-26 1998-03-26 Henry Uhlman Bryant Benzofluorene compounds, intermediates, compositions, and methods
WO1998048806A1 (en) * 1997-04-25 1998-11-05 Eli Lilly And Company Indene compounds having activity as serms
JP2003528858A (en) * 2000-03-27 2003-09-30 アクゾ・ノベル・エヌ・ベー Nonsteroidal tetracyclic compounds for estrogen-related treatments
TW200304371A (en) * 2002-02-22 2003-10-01 Akzo Nobel Nv Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors

Also Published As

Publication number Publication date
JP2004506712A (en) 2004-03-04
PL360885A1 (en) 2004-09-20
DE60114850D1 (en) 2005-12-15
KR20030027052A (en) 2003-04-03
BR0113444A (en) 2003-06-24
US6756375B2 (en) 2004-06-29
ATE309208T1 (en) 2005-11-15
NO20030759D0 (en) 2003-02-18
ZA200301239B (en) 2004-05-14
AU2001282101A1 (en) 2002-03-04
ECSP034488A (en) 2003-03-31
CN1447791A (en) 2003-10-08
US20040059004A1 (en) 2004-03-25
DE60114850T2 (en) 2006-05-24
AR030456A1 (en) 2003-08-20
CZ2003514A3 (en) 2003-10-15
NO20030759L (en) 2003-04-15
EP1313700B1 (en) 2005-11-09
ES2252273T3 (en) 2006-05-16
EP1313700A1 (en) 2003-05-28
IS6723A (en) 2003-02-20
HUP0303718A2 (en) 2004-03-01
MXPA03001591A (en) 2003-09-10
WO2002016316A1 (en) 2002-02-28
IL154408A0 (en) 2003-09-17
CA2420289A1 (en) 2002-02-28
SK2052003A3 (en) 2003-07-01

Similar Documents

Publication Publication Date Title
PE20020329A1 (en) DERIVATIVES OF 10-ARYL-11H-BENZO [b] FLUORENE AND ANALOGS AS STROGEN COMPOUNDS
GT199900146A (en) DERIVATIVES OF 4,4-BIARYLIPIPERIDINE.
EA199900937A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING VORIKONAZOL
PE20020593A1 (en) ISOINDOLIN-2-ONA TYPE GLUCOCINASE ACTIVATORS
GT200100137A (en) PRO-DRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES.
IL151172A0 (en) Amine derivatives, their preparation and use as bax modulators
ES2147309T3 (en) COMPOSITIONS OF LYOPHILIZED ONDANSETRON.
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
PE20020473A1 (en) COMBINED USE OF ACETYLCHOLINESTERASE INHIBITORS AND GABAa REVERSE AGONISTS FOR THE TREATMENT OF COGNITIVE DISORDERS
HK1028879A1 (en) Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
ES2151083T3 (en) ORAL COMPOSITIONS CONTAINING ONDANSETRON.
TNSN97044A1 (en) QUINOXALINEDONE DERIVATIVES, METHODS AND INTERMEDIATES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
PL361282A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
CO5200778A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A THERAPEUTICALLY EFFECTIVE AMOUNT OF B ENZIMIDAZOL, ADMINISTERED TO PREVENT AND TREAT CANCER AND INHIBIT METASTASIS
PT1272481E (en) 4-TRIFLUOROMETHYL-2H-BENZOPYRANES ANTISTROGENICS WITH SELECTIVE ESTROGENIC ACTION
ME00487B (en) Cyclosporine analogue mixtures and their use as immunomodulating agents
UY27979A1 (en) INDOLES REPLACED IN POSITION 2,4
BR0205812A (en) Benzimidazoles Useful in the Treatment of Sexual Dysfunction
ES2195089T3 (en) BENZOTIOPHENES AMORPHES, PREPARATION AND USE PROCEDURES.
ES2163715T3 (en) NAFTILO COMPOUNDS AND COMPOSITIONS.
DE69317418T2 (en) PHARMACEUTICAL COMPOSITIONS OF 5HT1 AGONISTIC ALKYL SULPHONAMIDES FOR RECTAL ADMINISTRATIONS
GB0019008D0 (en) Therapeutic compounds
ES2136198T3 (en) RECTAL COMPOSITIONS CONTAINING ODANSETRON IN THE FORM OF ITS FREE BASE.
PA8474401A1 (en) 3-KETO TRICYCLIC DERIVATIVES OF 6-0-METHYLERITHROMYCIN
ES2195313T3 (en) IMINO-AZA-ANTHRACICLINONE DERIVATIVES FOR THE TREATMENT OF AMYLOIDOSIS.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed